VentriPoint Diagnostics Ltd. 是一家醫療器材公司,致力於開發和推廣用於監測心臟病患者的診斷工具。公司總部位於安大略省多倫多市。该公司于2005年11月9日首次公開發行股票。公司專注於開發和推廣用於監測心臟病患者的診斷工具。公司開發了一系列針對所有心臟疾病和影像模式的應用,包括先天性心臟病、妊娠、肺動脈高壓、COVID-19、技術上困難的影像以及癌症患者的心臟毒性。公司提供將人工智慧應用於超音波心動圖的技術。其旗艦產品 Ventripoint Medical System(VMS+)可提升超音波心動圖的精確度,對心臟四個腔室的容積測量和射出分率提供接近心臟磁振造影(cMRI)等級的準確性。公司已開發出透過其3D ECHO與MRI軟體轉變心臟照護的解決方案。VMS系列產品由其專有的知識型重建技術(Knowledge Based Reconstruction)驅動,該技術經過十年研發而成,可提供與磁振造影相當的精確心臟容積測量。
VPTDF stock price ended at $0.09 on 星期四, after rising 0.00%
On the latest trading day Feb 05, 2026, the stock price of VPTDF rose by 0.00%, climbing from $0.09 to $0.09. Throughout the session, the stock experienced a volatility of 12.50%, with prices fluctuating between a daily low of $0.08 and a high of $0.09. Alongside this price increase, trading volume also rose by 53.2K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 99.6K shares were traded, amounting to a market value of approximately $15.4M.